AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.
Phase 2/3 trial in treatment-refractory Mycobacterium avium Complex continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of.
MENLO PARK - AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today.
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that.
Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex lung disease
On track to announce Phase 2 clinical data.